Ibrolipim
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584862

CAS#: 133208-93-2

Description: Ibrolipim increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol.


Chemical Structure

img
Ibrolipim
CAS# 133208-93-2

Theoretical Analysis

MedKoo Cat#: 584862
Name: Ibrolipim
CAS#: 133208-93-2
Chemical Formula: C19H20BrN2O4P
Exact Mass: 450.0344
Molecular Weight: 451.2568
Elemental Analysis: C, 50.57; H, 4.47; Br, 17.71; N, 6.21; O, 14.18; P, 6.86

Price and Availability

Size Price Availability Quantity
5.0mg USD 210.0 2 Weeks
10.0mg USD 350.0 2 Weeks
25.0mg USD 585.0 2 Weeks
Bulk inquiry

Synonym: Ibrolipim; NO-1886; OPF 009

IUPAC/Chemical Name: Diethyl (4-((4-bromo-2-cyanophenyl)carbamoyl)benzyl)phosphonate

InChi Key: KPRTURMJVWXURQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)

SMILES Code: O=C(C1=CC=C(C=C1)CP(OCC)(OCC)=O)NC2=CC=C(Br)C=C2C#N

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 451.2568 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nishimura M, Imai T, Morioka Y, Kuribayashi S, Kamataki T, Naito S. Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. Drug Metab Pharmacokinet. 2004 Dec;19(6):422-9. PubMed PMID: 15681896.

2: Kano S, Doi M. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats. Metabolism. 2006 Feb;55(2):151-8. PubMed PMID: 16423620.

3: Tsutsumi K, Inoue Y, Murase T. Effects of NO-1886, a lipoprotein lipase promoting agent, on homozygous and heterozygous Watanabe heritable hyperlipidaemic rabbits. Arzneimittelforschung. 2000 Feb;50(2):118-21. PubMed PMID: 10719613.

4: Liu Y, Wang ZB, Yin WD, Li QK, Cai MB, Yu J, Li HG, Zhang C, Zu XH. Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs. Lipids Health Dis. 2011 Jul 16;10:117. doi: 10.1186/1476-511X-10-117. PubMed PMID: 21762526; PubMed Central PMCID: PMC3155903.

5: Doi M, Kondo Y, Tsutsumi K. Lipoprotein lipase activator NO-1886 (ibrolipim) accelerates the mRNA expression of fatty acid oxidation-related enzymes in rat liver. Metabolism. 2003 Dec;52(12):1547-50. PubMed PMID: 14669153.

6: Zhang C, Yin W, Liao D, Huang L, Tang C, Tsutsumi K, Wang Z, Liu Y, Li Q, Hou H, Cai M, Xiao J. NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs. J Lipid Res. 2006 Sep;47(9):2055-63. Epub 2006 Jun 28. PubMed PMID: 16807312.

7: Wang ZB, Zeng HC, Wei HS, Yi GH, Yu J, Wang YT, Zhang YL, Yin WD. NO-1886 ameliorates glycogen metabolism in insulin-resistant HepG2 cells by GSK-3β signalling. J Pharm Pharmacol. 2012 Feb;64(2):293-301. doi: 10.1111/j.2042-7158.2011.01402.x. Epub 2011 Nov 21. PubMed PMID: 22221106.

8: Li Q, Yin W, Cai M, Liu Y, Hou H, Shen Q, Zhang C, Xiao J, Hu X, Wu Q, Funaki M, Nakaya Y. NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1. J Endocrinol. 2010 Jan;204(1):47-56. doi: 10.1677/JOE-09-0278. Epub 2009 Oct 8. PubMed PMID: 19815588.

9: Geldenhuys WJ, Aring D, Sadana P. A novel Lipoprotein lipase (LPL) agonist rescues the enzyme from inhibition by angiopoietin-like 4 (ANGPTL4). Bioorg Med Chem Lett. 2014 May 1;24(9):2163-7. doi: 10.1016/j.bmcl.2014.03.021. Epub 2014 Mar 18. PubMed PMID: 24703657.

10: Wu Q, Harada N, Nakamura A, Yoshida M, Mawatari K, Hattori A, Li Q, Shimohata T, Yinhua, Lian X, Nakano M, Hosaka T, Takahashi A, Nakaya Y. NO-1886, a lipoprotein lipase activator, attenuates contraction of rat intestinal ring preparations. J Med Invest. 2008 Feb;55(1-2):61-70. PubMed PMID: 18319547.

11: Yin W, Tsutsumi K, Yuan Z, Yang B. Effects of the lipoprotein lipase activator NO-1886 as a suppressor agent of atherosclerosis in aorta of mild diabetic rabbits. Arzneimittelforschung. 2002;52(8):610-4. PubMed PMID: 12236049.

12: Morioka Y, Nishimura M, Imai T, Suzuki S, Harada M, Satoh T, Naito S. Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver. Drug Metab Pharmacokinet. 2006 Feb;21(1):19-28. PubMed PMID: 16547390.

13: Yin W, Yuan Z, Tsutsumi K, Xie Y, Zhang Q, Wang Z, Fu G, Long G, Yang Y. A lipoprotein lipase-promoting agent, NO-1886, improves glucose and lipid metabolism in high fat, high sucrose-fed New Zealand white rabbits. Int J Exp Diabesity Res. 2003 Jan-Mar;4(1):27-34. PubMed PMID: 12745668; PubMed Central PMCID: PMC2480496.

14: Shimono K, Tsutsumi K, Yaguchi H, Omura M, Sasano H, Nishikawa T. Lipoprotein lipase promoting agent, NO-1886, modulates adrenal functions: species difference in effects of NO-1886 on steroidogenesis. Steroids. 1999 Jul;64(7):453-9. PubMed PMID: 10443901.

15: Cai M, Yin W, Li Q, Liao D, Tsutsumi K, Hou H, Liu Y, Zhang C, Li J, Wang Z, Xiao J. Effects of NO-1886 on inflammation-associated cytokines in high-fat/high-sucrose/high-cholesterol diet-fed miniature pigs. Eur J Pharmacol. 2006 Jul 1;540(1-3):139-46. Epub 2006 Apr 30. PubMed PMID: 16730700.

16: Kusunoki M, Tsutsumi K, Iwata K, Yin W, Nakamura T, Ogawa H, Nomura T, Mizutani K, Futenma A, Utsumi K, Miyata T. NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metabolism. 2005 Dec;54(12):1587-92. PubMed PMID: 16311090.

17: Kawamura I, Yamamoto N, Sakai F, Yamazaki H, Goto T. Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice. Anticancer Res. 1999 Sep-Oct;19(5B):4099-103. PubMed PMID: 10628360.

18: Hagi A, Hirai I, Kohri H, Tsutsumi K. The novel compound NO-1886 activates lipoprotein lipase in primary cultured adipose and skeletal muscle cells. Biol Pharm Bull. 1997 Oct;20(10):1108-10. PubMed PMID: 9353574.

19: Morioka Y, Harada M, Imai T, Naito S. Pharmacokinetics and metabolism of NO-1886, a lipoprotein lipase-promoting agent, in cynomolgus monkey. Xenobiotica. 2003 Dec;33(12):1247-60. PubMed PMID: 14742146.

20: Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, Wakabayashi K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2970-4. Epub 2005 Feb 14. PubMed PMID: 15710887; PubMed Central PMCID: PMC549478.